BETA


2018/0018(COD) Health technology assessment

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI WÖLKEN Tiemo (icon: S&D S&D) COLIN-OESTERLÉ Nathalie (icon: PPE PPE), KOPCIŃSKA Joanna (icon: ECR ECR), RIVASI Michèle (icon: Verts/ALE Verts/ALE)
Former Responsible Committee ENVI CABEZÓN RUIZ Soledad (icon: S&D S&D)
Former Committee Opinion EMPL
Former Committee Opinion IMCO BUŞOI Cristian-Silviu (icon: PPE PPE) Daniel DALTON (icon: ECR ECR), Kerstin WESTPHAL (icon: S&D S&D)
Former Committee Opinion JURI
Former Committee Opinion ECON
Former Committee Opinion FEMM
Former Committee Opinion ITRE WIERINCK Lieve (icon: ALDE ALDE)
Former Committee Legal Basis Opinion JURI VOSS Axel (icon: PPE PPE)
Lead committee dossier:
Legal Basis:
RoP 59-p4, TFEU 114

Events

2021/12/22
   Final act published in Official Journal
2021/12/15
   CSL - Draft final act
Documents
2021/12/15
   CSL - Final act signed
2021/12/13
   EP - Debate in Parliament
2021/12/13
   EP - Decision by Parliament, 2nd reading
Details

The European Parliament adopted a legislative resolution approving , without amendment, the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.

The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment throughout the EU. Health technology assessment (HTA) is an evidence-based scientific process that enables competent authorities to assess the relative effectiveness of new or existing health technologies. HTA focuses in particular on the added value of a health technology compared to other new or existing technologies.

Purpose of the Regulation

The new rules provide for Member States to cooperate in conducting joint clinical assessments and joint scientific consultations . They will also join forces to identify emerging health technologies.

The regulation establishes:

- a support framework and procedures for cooperation between Member States on health technologies at EU level;

- a mechanism whereby all information, analysis and evidence required for the common clinical assessment of health technologies is submitted by the health technology developer only once at EU level ;

- common rules and methods for the common clinical evaluation of health technologies.

Scope and timeframe

Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer . In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.

Coordination group

The Member States Coordination Group on Health Technology Assessment will be established.

The Council's position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group would be adopted by simple majority . By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.

The Coordination Group will ensure that the joint work carried out is of the highest quality, meets international standards of evidence-based medicine and is timely. It will operate in an independent, impartial and transparent manner.

Completion of the joint clinical evaluation

Upon receipt of the draft common clinical assessment reports and revised summary reports, the coordination group should review them. The coordination group should seek to approve the revised draft reports by consensus. Diverging scientific opinions, including the scientific basis for these opinions, should be included in the reports.

Obligations on Member States

Member States should ‘ give due consideration ’ to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.

Stakeholder involvement

The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.

Documents
2021/12/01
   EP - Committee recommendation tabled for plenary, 2nd reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the recommendation for second reading contained in the report by Tiemo WÖLKEN (S&D, DE), on the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.

The Council's position at first reading reflects the agreement reached between Parliament and the Council in the interinstitutional negotiations at early second reading stage.

As the committee responsible has already confirmed the outcome of these interinstitutional negotiations, it recommends that the plenary confirm the Council's position at first reading, without amendment.

The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment across the EU. It sets out four pillars around which Member States will work together at EU level, namely (1) joint clinical assessments, (2) joint scientific consultations, (3) identification of emerging health technologies, and (4) voluntary cooperation in areas outside the scope of mandatory cooperation.

The main points of the Council's position are as follows:

Scope and timeframe

Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer. In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.

Completion of the joint clinical assessment

With regard to the approval of the joint clinical assessment reports by the Coordination Group, the Council's position states that where consensus cannot be reached, the joint assessment should include the diverging scientific opinions and the scientific grounds on which these are based.

Voting regime of the Coordination Group

The Council position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group will be adopted by a simple majority. By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.

Obligations on Member States

Member States will be required to “give due consideration” to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.

Stakeholder involvement

The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.

Documents
2021/11/30
   EP - Vote in committee, 2nd reading
2021/11/25
   EP - Committee referral announced in Parliament, 2nd reading
2021/11/18
   CSL - Council position
Documents
2021/11/18
   CSL - Council position published
Documents
2021/11/17
   EC - Commission communication on Council's position
2021/11/10
   EP - Committee draft report
Documents
2021/07/16
   EP - Committee letter confirming interinstitutional agreement
Documents
2021/07/12
   EP - Approval in committee of the text agreed at early 2nd reading interinstitutional negotiations
Documents
2021/04/26
   EP - Committee decision to enter into interinstitutional negotiations announced in plenary (Rule 72)
2021/04/16
   EP - Committee decision to open interinstitutional negotiations after 1st reading in Parliament
2020/07/01
   FR_SENATE - Contribution
Documents
2019/04/16
   EC - Commission response to text adopted in plenary
Documents
2019/02/14
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted a resolution on the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.

Parliament’s position adopted at first reading under the ordinary legislative procedure amended the Commission proposal as follows:

The proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States.

The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general. It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks

Independence and transparency

Cooperation should be based on the principle of good governance, which encompasses transparency, objectivity, independent experience and fair procedures. Members insisted that trust is a precondition for successful cooperation.

A coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation.

In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed.

The coordination group shall ensure that relevant stakeholders and experts are consulted in its work.

In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.

Parliament stressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network, whose independence, transparency and impartiality of decisions would be guaranteed.

Joint clinical assessment report

The report shall be accompanied by a summary report, which shall contain at least the clinical data compared, the end-points, the comparators, the methodology, the clinical evidence used, and conclusions as regards efficacy, safety, and relative efficacy, the limits of the assessment, diverging views, a summary of the consultations carried out, and the observations made.

The report should be accompanied by a summary report including at least the following elements: (i) comparative clinical data, (ii) efficacy criteria, (iii) efficacy criteria, (iii) comparators, (iv) method, (iii) clinical data used, (iv) conclusions on effectiveness and safety, relative efficacy and evaluation limitations, (v) divergent positions, (vi) summary of consultations carried out and comments received.

The conclusions of the joint clinical assessment report shall include:

- an analysis of the relative effectiveness and safety of the health technology being assessed in terms of the clinical end-points relevant to the clinical entity and patient group chosen for the assessment, including mortality, morbidity and quality of life;

- the degree of certainty of relative effects based on the best available clinical data and compared to the best standard therapies.

Avoid duplication

In order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.

However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.

Financing

In order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding, as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.

Documents
2019/02/13
   EP - Debate in Parliament
2018/10/03
   EP - Results of vote in Parliament
2018/10/03
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted, by 576 votes to 56 with 41 abstentions, amendments to the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.

The matter was referred to the committee for interinstitutional negotiations.

The main amendments to the Commission proposal adopted in plenary session concern the following points:

Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States.

Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a precondition for successful cooperation.

The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general . It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks.

Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials.

Cooperation shall, inter alia :

promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools.

In the absence of a commonly agreed definition of what constitutes a high-quality innovation or therapeutic added value, Members called for such definitions to be adopted at EU level.

Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.

However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.

Independence and transparency : a coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation.

In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed.

The coordination group shall ensure that relevant stakeholders and experts are consulted in its work.

In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication . Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.

Membersstressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network , whose independence, transparency and impartiality of decisions would be guaranteed.

Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.

Documents
2018/10/03
   EP - Matter referred back to the committee responsible
2018/10/01
   EP - Debate in Parliament
2018/09/24
   EP - Committee report tabled for plenary, 1st reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the report by Soledad CABEZÓN RUIZ (S&D, ES) on the proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.

The committee recommended that the European Parliament's position adopted at first reading under the ordinary legislative procedure should amend the Commission's proposal as follows.

Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. It shall not interfere with the exclusive national competence of Member States for national pricing or reimbursement decisions.

Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a p recondition for successful cooperation.

HTA shall be used to promote innovations that produce the best results for patients and society in general . Health professionals, patients and health institutions need to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks. Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials.

Cooperation shall, inter alia :

promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools.

Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them.

However, according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group.

Transparency : in order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest , they shall withdraw from the meeting whilst the relevant agenda items are being discussed.

In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected.

Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.

Documents
2018/09/13
   EP - Vote in committee, 1st reading
2018/09/12
   EP - Committee opinion
Documents
2018/09/11
   EP - Specific opinion
Documents
2018/07/26
   EP - VOSS Axel (PPE) appointed as rapporteur in JURI
2018/07/20
   EP - Committee opinion
Documents
2018/06/18
   EP - Amendments tabled in committee
Documents
2018/06/18
   EP - Amendments tabled in committee
Documents
2018/05/04
   EP - Committee draft report
Documents
2018/05/01
   DE_BUNDESRAT - Contribution
Documents
2018/04/26
   IE_HOUSES-OF-OIREACHTAS - Contribution
Documents
2018/04/10
   PL_SENATE - Contribution
Documents
2018/04/03
   PT_PARLIAMENT - Contribution
Documents
2018/03/21
   EP - BUŞOI Cristian-Silviu (PPE) appointed as rapporteur in IMCO
2018/03/15
   EP - WIERINCK Lieve (ALDE) appointed as rapporteur in ITRE
2018/02/26
   EP - WÖLKEN Tiemo (S&D) appointed as rapporteur in ENVI
2018/02/26
   EP - CABEZÓN RUIZ Soledad (S&D) appointed as rapporteur in ENVI
2018/02/08
   EP - Committee referral announced in Parliament, 1st reading
2018/02/01
   EC - Document attached to the procedure
2018/02/01
   EC - Document attached to the procedure
2018/01/31
   EC - Legislative proposal published
Details

PURPOSE: foster cooperation between EU Member States in health technology assessment.

PROPOSED ACT: Regulation of the European Parliament and of the Council.

ROLE OF THE EUROPEAN PARLIAMENT: Parliament decides in accordance with the ordinary legislative procedure on an equal footing with Council.

BACKGROUND: health technology assessment (HTA) is a multidisciplinary process (covering medical, social, economic and ethical issues) and an evidence-based process that independently and objectively assesses a new or existing technology and compares it with other health technologies and / or the current standard of care.

Following the adoption of the Cross-Border Healthcare Directive ( Directive 2011/24/EU ), a voluntary European network of HTAs composed of national HTA agencies or bodies was set up (in 2013) to provide strategic and political guidance to the scientific and technical cooperation at Union-level.

While Member States have carried out some joint assessments within the framework of the EU co-funded joint actions, the production of output has been inefficient . Use of the results of the joint actions, including their joint clinical assessments, at Member State-level has remained low. The duplication of assessments on the same health technology by HTA authorities and bodies in different Member States within identical or similar timeframes has not been sufficiently addressed.

The European Parliament, in its resolution of 2 March 2017 called on the Commission to propose legislation on a European system for health technology assessment and to harmonise transparent health technology assessment criteria in order to assess the added therapeutic value of medicines.

IMPACT ASSESSMENT: four policy options were analysed. The preferred option is based on Option 4 ( permanent cooperation on common tools, procedures, early dialogues and joint clinical assessments ), integrating certain elements of Option 2 (project-based cooperation on HTA activities) as well as some adjustments (e.g. transitional arrangements for Member States and progressive implementation of the product scope for joint clinical assessments).

CONTENT: the proposed regulation aims to provide the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments of new medicines and certain new medical devices. Its general objectives are to ensure a better functioning of the internal market and to contribute to a high level of protection of human health. The specific objectives are to improve the availability of innovative health technologies for EU patients, to ensure an efficient use of resources and to improve the quality of HTA across th EU, and to improve business predictability.

Member States will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas:

1) Joint clinical assessments: these focus on the most innovative health technologies with the most Union-wide and public health impact. These assessments are limited to:

medicinal products undergoing the central marketing authorisation procedure, new active substances and existing products for which the marketing authorisation is extended to a new therapeutic indication; and certain classes of medical devices and in vitro diagnostic medical devices which have been selected by the Coordination Group set up under the Regulation.

Following the end of a transitional period , participation in the assessments and use of the joint clinical assessment reports at Member State level will be mandatory. Member States will continue to carry out non-clinical assessments (e.g. economic, organisational, ethical) of health technologies and make decisions on pricing and reimbursement.

2) Joint scientific consultations : these allow a developer in the development phase of a health technology to seek the advice of HTA authorities and bodies on the data and evidence likely to be required as part of a potential future joint clinical assessment.

3) Identification of emerging health technologies : This exercise will act as a key input for the annual work programmes, helping to identify at an early stage of their development, the health technologies expected to have a major impact on patients. The Coordination Group will fully consult with all relevant interest groups during this exercise.

4) Voluntary cooperation in other areas : this cooperation could include the assessment of health technologies other than medicinal products or medical devices, non-clinical assessments or collaborative assessments of medical devices not subject to common clinical assessments.

Lastly, the proposal lays down common implementing rules in order to ensure harmonisation of the way in which Member States carry out clinical assessments. A key objective of these rules will be to ensure that clinical assessments, whether at EU or at Member State level, are carried out in an independent and transparent manner, free from conflicts of interests.

BUDGETARY IMPLICATIONS: the implementation of the proposal has no impact on the current Multiannual Financial Framework 2014-2020 as the current cooperation on HTA is financed by the Public Health Programme. The financial impact on the EU budget post-2020 will be part of the Commission's proposals for the next Multiannual Financial Framework.

DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union.

Documents

Activities

Votes

A8-0289/2018 - Soledad Cabezón Ruiz - Am 209 03/10/2018 12:39:29.000 #

2018/10/03 Outcome: -: 565, +: 76, 0: 27
IE ?? CY LV EL MT LU EE DK LT SI FI HU HR PT SK CZ BE BG SE AT IT NL RO ES FR PL GB DE
Total
8
2
6
3
19
6
5
5
12
10
8
13
15
10
19
11
17
18
16
19
17
66
25
30
49
68
45
57
87
icon: GUE/NGL GUE/NGL
40

Ireland GUE/NGL

3

Cyprus GUE/NGL

2

Denmark GUE/NGL

For (1)

1

Finland GUE/NGL

For (1)

1

Czechia GUE/NGL

1

Sweden GUE/NGL

For (1)

1

Italy GUE/NGL

2

Netherlands GUE/NGL

3

United Kingdom GUE/NGL

1
icon: ENF ENF
28

Belgium ENF

Against (1)

1

Austria ENF

3

Netherlands ENF

4

Poland ENF

Abstain (1)

1

Germany ENF

Against (1)

1
icon: EFDD EFDD
35

Lithuania EFDD

For (1)

1

Poland EFDD

1

Germany EFDD

Against (1)

1
icon: NI NI
17

NI

For (1)

Against (1)

2

Denmark NI

Against (1)

1

Hungary NI

For (1)

1

United Kingdom NI

Against (2)

Abstain (2)

4

Germany NI

Against (1)

2
icon: Verts/ALE Verts/ALE
51

Luxembourg Verts/ALE

Against (1)

1

Estonia Verts/ALE

Against (1)

1

Denmark Verts/ALE

Against (1)

1

Lithuania Verts/ALE

Against (1)

1

Slovenia Verts/ALE

Against (1)

1

Finland Verts/ALE

Against (1)

1

Hungary Verts/ALE

2

Croatia Verts/ALE

Against (1)

1

Belgium Verts/ALE

2

Austria Verts/ALE

3

Italy Verts/ALE

Against (1)

1

Netherlands Verts/ALE

2

United Kingdom Verts/ALE

6
icon: ECR ECR
60

Cyprus ECR

Against (1)

1

Greece ECR

For (1)

1

Denmark ECR

Against (1)

3

Lithuania ECR

Against (1)

1

Finland ECR

2

Croatia ECR

Against (1)

1

Slovakia ECR

2

Czechia ECR

2

Belgium ECR

2

Bulgaria ECR

2

Sweden ECR

2

Italy ECR

2

Netherlands ECR

2

Romania ECR

2
icon: ALDE ALDE
65

Ireland ALDE

For (1)

1

Latvia ALDE

1

Luxembourg ALDE

Against (1)

1

Estonia ALDE

Against (2)

2

Denmark ALDE

3

Slovenia ALDE

Against (1)

1

Croatia ALDE

2

Portugal ALDE

1

Austria ALDE

Against (1)

1

Romania ALDE

3

United Kingdom ALDE

Against (1)

1

Germany ALDE

2
icon: S&D S&D
172

Cyprus S&D

2

Greece S&D

Abstain (1)

4

Malta S&D

For (1)

Against (2)

3

Estonia S&D

Against (1)

1
3

Lithuania S&D

2

Slovenia S&D

Against (1)

1

Finland S&D

2

Hungary S&D

2

Croatia S&D

2

Slovakia S&D

3

Czechia S&D

4
3

Netherlands S&D

Against (2)

2
icon: PPE PPE
198

Cyprus PPE

Against (1)

1

Latvia PPE

2

Luxembourg PPE

3

Estonia PPE

Against (1)

1

Lithuania PPE

2

Finland PPE

3

Belgium PPE

3

United Kingdom PPE

2

A8-0289/2018 - Soledad Cabezón Ruiz - Proposition de la Commission 03/10/2018 12:44:23.000 #

2018/10/03 Outcome: +: 576, -: 56, 0: 41
DE IT ES PL FR RO AT BE BG HU CZ SE FI PT GB NL SK HR LT EL IE SI DK MT LU EE LV CY ??
Total
87
68
49
46
68
30
18
18
16
15
18
19
13
19
57
25
11
10
10
19
8
8
12
6
5
5
3
6
2
icon: PPE PPE
198

Belgium PPE

3

United Kingdom PPE

2

Lithuania PPE

2

Luxembourg PPE

3

Estonia PPE

For (1)

1

Latvia PPE

2

Cyprus PPE

1
icon: S&D S&D
172

Hungary S&D

2

Netherlands S&D

For (2)

2
3

Croatia S&D

2

Slovenia S&D

For (1)

1

Malta S&D

3

Estonia S&D

For (1)

1

Cyprus S&D

2
icon: ALDE ALDE
65

Germany ALDE

2

Romania ALDE

3

Austria ALDE

For (1)

1

Portugal ALDE

1

United Kingdom ALDE

1

Croatia ALDE

2

Ireland ALDE

For (1)

1

Slovenia ALDE

For (1)

1

Luxembourg ALDE

For (1)

1

Estonia ALDE

2

Latvia ALDE

1
icon: Verts/ALE Verts/ALE
51

Italy Verts/ALE

For (1)

1

Austria Verts/ALE

3

Belgium Verts/ALE

2

Hungary Verts/ALE

2

Finland Verts/ALE

For (1)

1

Netherlands Verts/ALE

2

Croatia Verts/ALE

For (1)

1

Lithuania Verts/ALE

For (1)

1

Slovenia Verts/ALE

For (1)

1

Denmark Verts/ALE

For (1)

1

Luxembourg Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1
icon: ECR ECR
60

Italy ECR

2

Romania ECR

2

Belgium ECR

2

Bulgaria ECR

2

Czechia ECR

2

Sweden ECR

2
2

Netherlands ECR

2

Slovakia ECR

2

Croatia ECR

For (1)

1

Lithuania ECR

Abstain (1)

1

Greece ECR

For (1)

1

Cyprus ECR

1
icon: GUE/NGL GUE/NGL
40

Italy GUE/NGL

2

Czechia GUE/NGL

1

Sweden GUE/NGL

Against (1)

1

Finland GUE/NGL

For (1)

1

Portugal GUE/NGL

For (1)

4

United Kingdom GUE/NGL

1

Netherlands GUE/NGL

3

Ireland GUE/NGL

3

Denmark GUE/NGL

Against (1)

1

Cyprus GUE/NGL

2
icon: EFDD EFDD
36

Germany EFDD

Against (1)

1

Poland EFDD

1

Czechia EFDD

Against (1)

1

Lithuania EFDD

For (1)

1
icon: NI NI
18

Germany NI

Against (1)

2

Hungary NI

For (1)

1

United Kingdom NI

Abstain (1)

4

Denmark NI

1
icon: ENF ENF
31

Germany ENF

Against (1)

1

Poland ENF

Abstain (1)

1

Belgium ENF

Abstain (1)

1

Netherlands ENF

4
AmendmentsDossier
697 2018/0018(COD)
2018/05/25 ITRE 126 amendments...
source: 622.255
2018/06/13 IMCO 144 amendments...
source: 623.737
2018/06/15 ENVI 192 amendments...
source: 623.758
2018/06/18 ENVI 235 amendments...
source: 623.757

History

(these mark the time of scraping, not the official date of the change)

docs/0
date
2018-01-31T00:00:00
docs
summary
type
Legislative proposal
body
EC
docs/4
date
2018-05-04T00:00:00
docs
title: PE620.932
type
Reasoned opinion
body
DE_BUNDESTAG
docs/5
date
2018-05-30T00:00:00
docs
url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/parlements_nationaux/com/2018/0051/CZ_CHAMBER_AVIS-COM(2018)0051_EN.docx title: PE620.962
type
Reasoned opinion
body
CZ_CHAMBER
docs/6
date
2018-05-30T00:00:00
docs
title: PE620.963
type
Reasoned opinion
body
FR_SENATE
docs/8
date
2019-04-16T00:00:00
docs
title: SP(2019)354
type
Commission response to text adopted in plenary
body
EC
docs/9
date
2021-07-16T00:00:00
docs
url: http://www.europarl.europa.eu/RegData/commissions/envi/lpag/2021/08-23/ENVI_LA(2021)696384_EN.pdf title: PE696.384
type
Committee letter confirming interinstitutional agreement
body
EP
docs/11
date
2021-11-17T00:00:00
docs
type
Commission communication on Council's position
body
EC
docs/11
date
2018-09-11T00:00:00
docs
title: PE627.728
type
Amendments tabled in committee
body
EP
docs/13
date
2018-09-13T00:00:00
docs
url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/parlements_nationaux/com/2018/0051/PL_SEJM_AVIS-COM(2018)0051_EN.docx title: PE626.700
type
Reasoned opinion
body
PL_SEJM
docs/14
date
2019-04-16T00:00:00
docs
title: SP(2019)354
type
Commission response to text adopted in plenary
body
EC
docs/14
date
2018-04-10T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
PL_SENATE
docs/14/docs/0/url
/oeil/spdoc.do?i=31544&j=0&l=en
docs/15
date
2018-04-03T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
PT_PARLIAMENT
docs/16
date
2018-04-26T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
IE_HOUSES-OF-OIREACHTAS
docs/16
date
2021-11-17T00:00:00
docs
type
Commission communication on Council's position
body
EC
docs/17
date
2018-05-01T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
DE_BUNDESRAT
docs/18
date
2020-07-01T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
FR_SENATE
docs/18
date
2021-12-01T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2021-0334_EN.html title: A9-0334/2021
summary
type
Committee recommendation tabled for plenary, 2nd reading
body
EP
docs/19
date
2021-12-13T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0484_EN.html title: T9-0484/2021
type
Text adopted by Parliament, 2nd reading
body
EP
docs/21
date
2018-04-11T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
PL_SENATE
docs/22
date
2018-04-04T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
PT_PARLIAMENT
docs/23
date
2018-04-27T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
IE_HOUSES-OF-OIREACHTAS
docs/24
date
2018-05-02T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
DE_BUNDESRAT
docs/25
date
2020-07-02T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
FR_SENATE
events/0
date
2018-01-31T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/11
date
2021-07-13T00:00:00
type
Approval in committee of the text agreed at early 2nd reading interinstitutional negotiations
body
EP
docs
title: PE696.384
events/12
date
2021-07-12T00:00:00
type
Approval in committee of the text agreed at early 2nd reading interinstitutional negotiations
body
EP
docs
url: http://www.europarl.europa.eu/RegData/commissions/envi/lpag/2021/08-23/ENVI_LA(2021)696384_EN.pdf title: PE696.384
events/13
date
2021-11-18T00:00:00
type
Council position published
body
CSL
docs
title: 10531/3/2021
events/15
date
2021-12-13T00:00:00
type
Decision by Parliament, 2nd reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0484_EN.html title: T9-0484/2021
events/16
date
2021-12-01T00:00:00
type
Committee recommendation tabled for plenary, 2nd reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2021-0334_EN.html title: A9-0334/2021
summary
events/18
date
2021-12-13T00:00:00
type
Decision by Parliament, 2nd reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0484_EN.html title: T9-0484/2021
events/18/summary
  • The European Parliament adopted a legislative resolution approving , without amendment, the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
  • The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment throughout the EU. Health technology assessment (HTA) is an evidence-based scientific process that enables competent authorities to assess the relative effectiveness of new or existing health technologies. HTA focuses in particular on the added value of a health technology compared to other new or existing technologies.
  • Purpose of the Regulation
  • The new rules provide for Member States to cooperate in conducting joint clinical assessments and joint scientific consultations . They will also join forces to identify emerging health technologies.
  • The regulation establishes:
  • - a support framework and procedures for cooperation between Member States on health technologies at EU level;
  • - a mechanism whereby all information, analysis and evidence required for the common clinical assessment of health technologies is submitted by the health technology developer only once at EU level ;
  • - common rules and methods for the common clinical evaluation of health technologies.
  • Scope and timeframe
  • Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer . In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.
  • Coordination group
  • The Member States Coordination Group on Health Technology Assessment will be established.
  • The Council's position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group would be adopted by simple majority . By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.
  • The Coordination Group will ensure that the joint work carried out is of the highest quality, meets international standards of evidence-based medicine and is timely. It will operate in an independent, impartial and transparent manner.
  • Completion of the joint clinical evaluation
  • Upon receipt of the draft common clinical assessment reports and revised summary reports, the coordination group should review them. The coordination group should seek to approve the revised draft reports by consensus. Diverging scientific opinions, including the scientific basis for these opinions, should be included in the reports.
  • Obligations on Member States
  • Member States should ‘ give due consideration ’ to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.
  • Stakeholder involvement
  • The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.
links/Research document/url
Old
http://www.europarl.europa.eu/thinktank/en/document.html?reference=EPRS_BRI(2018)614772
New
https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI(2018)614772
events/17
date
2021-12-22T00:00:00
type
Final act published in Official Journal
docs
procedure/final
title
Regulation 2021/2282
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32021R2282
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
docs/19
date
2021-12-13T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0484_EN.html title: T9-0484/2021
type
Text adopted by Parliament, 2nd reading
body
EP
docs/25
date
2020-07-02T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
FR_SENATE
events/15
date
2021-12-13T00:00:00
type
Decision by Parliament, 2nd reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2021-0484_EN.html title: T9-0484/2021
procedure/stage_reached
Old
Awaiting Parliament 2nd reading
New
Procedure completed, awaiting publication in Official Journal
docs/24
date
2020-07-02T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
FR_SENATE
events/14
date
2021-12-13T00:00:00
type
Debate in Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/CRE-9-2021-12-13-TOC_EN.html title: Debate in Parliament
events/15
date
2021-12-15T00:00:00
type
Final act signed
body
CSL
forecasts
  • date: 2021-12-13T00:00:00 title: Debate in plenary scheduled
docs/18/summary
  • The Committee on the Environment, Public Health and Food Safety adopted the recommendation for second reading contained in the report by Tiemo WÖLKEN (S&D, DE), on the Council's position at first reading with a view to the adoption of a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU.
  • The Council's position at first reading reflects the agreement reached between Parliament and the Council in the interinstitutional negotiations at early second reading stage.
  • As the committee responsible has already confirmed the outcome of these interinstitutional negotiations, it recommends that the plenary confirm the Council's position at first reading, without amendment.
  • The proposed regulation includes provisions on the use of common methods, procedures and tools for health technology assessment across the EU. It sets out four pillars around which Member States will work together at EU level, namely (1) joint clinical assessments, (2) joint scientific consultations, (3) identification of emerging health technologies, and (4) voluntary cooperation in areas outside the scope of mandatory cooperation.
  • The main points of the Council's position are as follows:
  • Scope and timeframe
  • Advanced therapy medicinal products would be subject to a joint clinical assessment at the date of application of the regulation, as would medicinal products containing new active substances for the treatment of cancer. In addition, orphan medicinal products and all remaining medicinal products within the scope of the Regulation would be added three and five years respectively after the date of application of the Regulation.
  • Completion of the joint clinical assessment
  • With regard to the approval of the joint clinical assessment reports by the Coordination Group, the Council's position states that where consensus cannot be reached, the joint assessment should include the diverging scientific opinions and the scientific grounds on which these are based.
  • Voting regime of the Coordination Group
  • The Council position provides for the use of different types of majorities, depending on the type of decisions adopted. The default rule would be that, where consensus cannot be reached, decisions of the Coordination Group will be adopted by a simple majority. By way of derogation, a qualified majority would be required for the adoption of the annual work programme and the annual report, as well as for the definition of the strategic direction to be given to the work of the sub-groups.
  • Obligations on Member States
  • Member States will be required to “give due consideration” to the joint clinical assessment reports. A certain number of safeguards were introduced to strengthen obligations on Member States, namely the requirement to annex the joint clinical assessment report to the national health technology assessment and to report on how each joint clinical assessment report was given due consideration in the health technology assessment at national level.
  • Stakeholder involvement
  • The Council position states that the subgroups should ensure that patients, clinical experts and other relevant experts participate in the assessment by having the opportunity to provide input on the draft reports. Provisions were also agreed to ensure transparency and absence of conflict of interest during the joint work.
forecasts/0/date
Old
2021-12-14T00:00:00
New
2021-12-13T00:00:00
docs/19
date
2021-12-15T00:00:00
docs
title: 00080/2021/LEX
type
Draft final act
body
CSL
docs/18
date
2021-12-01T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/A-9-2021-0334_EN.html title: A9-0334/2021
type
Committee recommendation tabled for plenary, 2nd reading
body
EP
events/12
date
2021-11-25T00:00:00
type
Committee referral announced in Parliament, 2nd reading
body
EP
events/13
date
2021-11-30T00:00:00
type
Vote in committee, 2nd reading
body
EP
forecasts
  • date: 2021-12-14T00:00:00 title: Debate in plenary scheduled
docs/17
date
2021-11-18T00:00:00
docs
title: 10531/3/2021
type
Council position
body
CSL
docs/16/docs/0
url
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2021&nu_doc=0696
title
EUR-Lex
docs/16
date
2021-11-17T00:00:00
docs
title: COM(2021)0696
type
Commission communication on Council's position
body
EC
docs/15
date
2021-11-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/ENVI-PR-699301_EN.html title: PE699.301
type
Committee draft report
body
EP
procedure/dossier_of_the_committee/0
ENVI/9/05741
procedure/dossier_of_the_committee/0
ENVI/8/12220
procedure/stage_reached
Old
Awaiting Council's 1st reading position
New
Awaiting Parliament 2nd reading
events/11
date
2021-07-13T00:00:00
type
Approval in committee of the text agreed at early 2nd reading interinstitutional negotiations
body
EP
docs
title: PE696.384
docs/0
date
2018-01-31T00:00:00
docs
summary
type
Legislative proposal
body
EC
events/0
date
2018-01-31T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/7
date
2019-02-13T00:00:00
type
Debate in Parliament
body
EP
events/7/docs
  • url: https://www.europarl.europa.eu/doceo/document/CRE-8-2019-02-13-TOC_EN.html title: Debate in Parliament
events/8
date
2019-02-13T00:00:00
type
Debate in Parliament
body
EP
events/1/body
EP
events/2/body
EP
events/3/body
EP
events/6/body
EP
events/9/body
EP
docs/2/docs/0/url
https://www.europarl.europa.eu/doceo/document/ENVI-PR-622011_EN.html
docs/6/docs/0/url
https://www.europarl.europa.eu/doceo/document/ENVI-AM-623757_EN.html
docs/7/docs/0/url
https://www.europarl.europa.eu/doceo/document/ENVI-AM-623758_EN.html
docs/8/docs/0/url
https://www.europarl.europa.eu/doceo/document/IMCO-AD-622139_EN.html
docs/9/docs/0/url
https://www.europarl.europa.eu/doceo/document/JURI-AL-627727_EN.html
docs/11/docs/0/url
https://www.europarl.europa.eu/doceo/document/ITRE-AD-620890_EN.html
events/4/docs
  • url: https://www.europarl.europa.eu/doceo/document/CRE-8-2018-10-01-TOC_EN.html title: Debate in Parliament
events/10
date
2021-04-16T00:00:00
type
Committee decision to open interinstitutional negotiations after 1st reading in Parliament
body
EP
events/11
date
2021-04-26T00:00:00
type
Committee decision to enter into interinstitutional negotiations announced in plenary (Rule 72)
body
EP
docs/0
date
2018-01-31T00:00:00
docs
summary
type
Legislative proposal
body
EC
events/0
date
2018-01-31T00:00:00
type
Legislative proposal published
body
EC
docs
summary
docs/0
date
2018-01-31T00:00:00
docs
summary
type
Legislative proposal
body
EC
docs/2
date
2018-05-04T00:00:00
docs
title: PE622.011
type
Committee draft report
body
EP
docs/2/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011
docs/3
date
2018-05-04T00:00:00
docs
title: PE622.011
type
Committee draft report
body
EP
docs/6
date
2018-06-18T00:00:00
docs
title: PE623.757
type
Amendments tabled in committee
body
EP
docs/6/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757
docs/7
date
2018-06-18T00:00:00
docs
title: PE623.757
type
Amendments tabled in committee
body
EP
docs/7
date
2018-06-18T00:00:00
docs
title: PE623.758
type
Amendments tabled in committee
body
EP
docs/7/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758
docs/8
date
2018-06-18T00:00:00
docs
title: PE623.758
type
Amendments tabled in committee
body
EP
docs/8
date
2018-07-20T00:00:00
docs
title: PE622.139
committee
IMCO
type
Committee opinion
body
EP
docs/8/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
docs/9
date
2018-07-20T00:00:00
docs
title: PE622.139
committee
IMCO
type
Committee opinion
body
EP
docs/9
date
2018-09-11T00:00:00
docs
title: PE627.727
committee
JURI
type
Specific opinion
body
EP
docs/9/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/10
date
2018-09-11T00:00:00
docs
title: PE627.727
committee
JURI
type
Specific opinion
body
EP
docs/11
date
2018-09-12T00:00:00
docs
title: PE620.890
committee
ITRE
type
Committee opinion
body
EP
docs/11/docs/0/url
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
docs/12
date
2018-09-12T00:00:00
docs
title: PE620.890
committee
ITRE
type
Committee opinion
body
EP
events/0
date
2018-02-08T00:00:00
type
Committee referral announced in Parliament, 1st reading
events/0
date
2018-01-31T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/1
date
2018-09-13T00:00:00
type
Vote in committee, 1st reading
events/1
date
2018-02-08T00:00:00
type
Committee referral announced in Parliament, 1st reading/single reading
body
EP
events/2
date
2018-09-24T00:00:00
type
Committee report tabled for plenary, 1st reading
docs
url: https://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html title: A8-0289/2018
summary
events/2
date
2018-09-13T00:00:00
type
Vote in committee, 1st reading/single reading
body
EP
events/3
date
2018-10-01T00:00:00
type
Debate in Parliament
body
EP
events/3
date
2018-09-24T00:00:00
type
Committee report tabled for plenary, 1st reading/single reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html title: A8-0289/2018
summary
events/4
date
2018-10-01T00:00:00
type
Debate in Parliament
body
EP
events/4/docs
  • url: https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRE title: Debate in Parliament
events/5
date
2018-10-03T00:00:00
type
Decision by Parliament, 1st reading
docs
url: https://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html title: T8-0369/2018
summary
events/6
date
2018-10-03T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html title: T8-0369/2018
summary
events/7
date
2019-02-13T00:00:00
type
Debate in Parliament
body
EP
events/8
date
2019-02-13T00:00:00
type
Debate in Parliament
body
EP
events/8
date
2019-02-14T00:00:00
type
Decision by Parliament, 1st reading
docs
url: https://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html title: T8-0120/2019
summary
events/8/docs
  • url: https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRE title: Debate in Parliament
events/9
date
2019-02-14T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html title: T8-0120/2019
summary
committees/0
type
Responsible Committee
body
EP
committee_full
Environment, Public Health and Food Safety
committee
ENVI
associated
False
rapporteur
name: WÖLKEN Tiemo date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Economic and Monetary Affairs
committee
ECON
opinion
False
committees/1
type
Former Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Economic and Monetary Affairs
committee
ECON
opinion
False
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
opinion
False
committees/2/type
Old
Committee Opinion
New
Former Committee Opinion
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
opinion
False
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/3/type
Old
Committee Opinion
New
Former Committee Opinion
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/4/type
Old
Committee Opinion
New
Former Committee Opinion
committees/5
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/5
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
opinion
False
committees/5/type
Old
Committee Opinion
New
Former Committee Opinion
committees/6
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
opinion
False
committees/6
type
Committee Opinion
body
EP
associated
False
committee_full
Womens Rights and Gender Equality
committee
FEMM
opinion
False
committees/6/type
Old
Committee Opinion
New
Former Committee Opinion
committees/7
type
Committee Opinion
body
EP
associated
False
committee_full
Womens Rights and Gender Equality
committee
FEMM
opinion
False
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/7/type
Old
Committee Opinion
New
Former Committee Opinion
committees/8
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/8/type
Old
Committee Legal Basis Opinion
New
Former Committee Legal Basis Opinion
docs/8/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/11/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ??? abbr: Unknown Group
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: ??? abbr: Unknown Group
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: ??? abbr: Unknown Group
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ??? abbr: Unknown Group
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ALDE - Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ALDE - Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ??? abbr: Unknown Group
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: ??? abbr: Unknown Group
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: ??? abbr: Unknown Group
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: ??? abbr: Unknown Group
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: ??? abbr: Unknown Group
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
docs/8/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/11/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/7/rapporteur/0/mepref
96761
procedure/Modified legal basis
Rules of Procedure EP 159
procedure/Other legal basis
Rules of Procedure EP 159
procedure/stage_reached
Old
Awaiting Council 1st reading position / budgetary conciliation convocation
New
Awaiting Council's 1st reading position
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/18
date
2020-07-02T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051
type
Contribution
body
FR_SENATE
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/8/docs/0/url
Old
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
docs/9/docs/0/url
Old
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/11/docs/0/url
Old
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
docs/2/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757
docs/7/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758
docs/8/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
New
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
https://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/11/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
New
http://httsp://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03
events/3/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html
events/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRE
New
https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRE
events/6/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html
New
https://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html
events/8/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRE
New
https://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRE
events/9/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html
New
https://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/13/body
EC
events/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0289&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-8-2018-0289_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0369
New
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0369_EN.html
events/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2019-0120
New
http://www.europarl.europa.eu/doceo/document/TA-8-2019-0120_EN.html
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
events/5
date
2019-02-14T00:00:00
type
Results of vote in Parliament
body
EP
docs
url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=31544&l=en title: Results of vote in Parliament
events/5/date
Old
2019-02-14T00:00:00
New
2018-10-03T00:00:00
events/8
date
2019-02-14T00:00:00
type
Results of vote in Parliament
body
EP
docs
url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=31544&l=en title: Results of vote in Parliament
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: CABEZÓN RUIZ Soledad date: 2018-02-26T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2018-02-26T00:00:00
rapporteur
name: CABEZÓN RUIZ Soledad group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: WIERINCK Lieve date: 2018-03-15T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2018-03-15T00:00:00
rapporteur
name: WIERINCK Lieve group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: BUŞOI Cristian-Silviu date: 2018-03-21T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2018-03-21T00:00:00
rapporteur
name: BUŞOI Cristian-Silviu group: European People's Party (Christian Democrats) abbr: PPE
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
rapporteur
name: VOSS Axel date: 2018-07-26T00:00:00 group: European People's Party (Christian Democrats) abbr: PPE
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2018-07-26T00:00:00
rapporteur
name: VOSS Axel group: European People's Party (Christian Democrats) abbr: PPE
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
docs/9/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727
New
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727&secondRef=01
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2018-03-21T00:00:00
rapporteur
name: BUŞOI Cristian-Silviu group: European People's Party (Christian Democrats) abbr: PPE
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2018-03-21T00:00:00
rapporteur
name: BUŞOI Cristian-Silviu group: Group of European People's Party abbr: EPP
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2018-07-26T00:00:00
rapporteur
name: VOSS Axel group: European People's Party (Christian Democrats) abbr: PPE
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2018-07-26T00:00:00
rapporteur
name: VOSS Axel group: Group of European People's Party abbr: EPP
activities
  • date: 2018-01-31T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2018/0051/COM_COM(2018)0051_EN.pdf title: COM(2018)0051 type: Legislative proposal published celexid: CELEX:52018PC0051:EN body: EC commission: DG: url: http://ec.europa.eu/info/departments/health-and-food-safety_en title: Health and Food Safety Commissioner: ANDRIUKAITIS Vytenis Povilas type: Legislative proposal published
  • date: 2018-02-08T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Economic and Monetary Affairs committee: ECON body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL body: EP shadows: group: EPP name: GROSSETÊTE Françoise group: ECR name: PIECHA Bolesław G. group: ALDE name: MEISSNER Gesine group: GUE/NGL name: KONEČNÁ Kateřina group: Verts/ALE name: RIVASI Michèle group: EFD name: PEDICINI Piernicola group: ENF name: MÉLIN Joëlle responsible: True committee: ENVI date: 2018-02-26T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: CABEZÓN RUIZ Soledad body: EP responsible: False committee_full: Women’s Rights and Gender Equality committee: FEMM body: EP responsible: False committee: IMCO date: 2018-03-21T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: EPP name: BUŞOI Cristian-Silviu body: EP responsible: False committee: ITRE date: 2018-03-15T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: WIERINCK Lieve body: EP responsible: False committee_full: Legal Affairs committee: JURI body: EP responsible: None committee: JURI date: 2018-07-26T00:00:00 committee_full: Legal Affairs rapporteur: group: EPP name: VOSS Axel
commission
  • body: EC dg: Health and Food Safety commissioner: ANDRIUKAITIS Vytenis Povilas
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2018-02-26T00:00:00
rapporteur
name: CABEZÓN RUIZ Soledad group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
committees/0
body
EP
responsible
False
committee_full
Economic and Monetary Affairs
committee
ECON
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Economic and Monetary Affairs
committee
ECON
opinion
False
committees/1
body
EP
responsible
False
committee_full
Employment and Social Affairs
committee
EMPL
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Employment and Social Affairs
committee
EMPL
opinion
False
committees/2
body
EP
shadows
responsible
True
committee
ENVI
date
2018-02-26T00:00:00
committee_full
Environment, Public Health and Food Safety
rapporteur
group: S&D name: CABEZÓN RUIZ Soledad
committees/3
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2018-03-15T00:00:00
rapporteur
name: WIERINCK Lieve group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/3
body
EP
responsible
False
committee_full
Women’s Rights and Gender Equality
committee
FEMM
committees/4
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2018-03-21T00:00:00
rapporteur
name: BUŞOI Cristian-Silviu group: Group of European People's Party abbr: EPP
committees/4
body
EP
responsible
False
committee
IMCO
date
2018-03-21T00:00:00
committee_full
Internal Market and Consumer Protection
rapporteur
group: EPP name: BUŞOI Cristian-Silviu
committees/5
type
Committee Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
opinion
False
committees/5
body
EP
responsible
False
committee
ITRE
date
2018-03-15T00:00:00
committee_full
Industry, Research and Energy
rapporteur
group: ALDE name: WIERINCK Lieve
committees/6
type
Committee Opinion
body
EP
associated
False
committee_full
Womens Rights and Gender Equality
committee
FEMM
opinion
False
committees/6
body
EP
responsible
False
committee_full
Legal Affairs
committee
JURI
committees/7
type
Committee Legal Basis Opinion
body
EP
associated
False
committee_full
Legal Affairs
committee
JURI
date
2018-07-26T00:00:00
rapporteur
name: VOSS Axel group: Group of European People's Party abbr: EPP
committees/7
body
EP
responsible
None
committee
JURI
date
2018-07-26T00:00:00
committee_full
Legal Affairs
rapporteur
group: EPP name: VOSS Axel
docs
  • date: 2018-02-01T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2018:0041:FIN:EN:PDF title: EUR-Lex title: SWD(2018)0041 type: Document attached to the procedure body: EC
  • date: 2018-02-01T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2018:0042:FIN:EN:PDF title: EUR-Lex title: SWD(2018)0042 type: Document attached to the procedure body: EC
  • date: 2018-05-04T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.011 title: PE622.011 type: Committee draft report body: EP
  • date: 2018-05-04T00:00:00 docs: title: PE620.932 type: Reasoned opinion body: DE_BUNDESTAG
  • date: 2018-05-30T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/parlements_nationaux/com/2018/0051/CZ_CHAMBER_AVIS-COM(2018)0051_EN.docx title: PE620.962 type: Reasoned opinion body: CZ_CHAMBER
  • date: 2018-05-30T00:00:00 docs: title: PE620.963 type: Reasoned opinion body: FR_SENATE
  • date: 2018-06-18T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.757 title: PE623.757 type: Amendments tabled in committee body: EP
  • date: 2018-06-18T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE623.758 title: PE623.758 type: Amendments tabled in committee body: EP
  • date: 2018-07-20T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE622.139&secondRef=03 title: PE622.139 committee: IMCO type: Committee opinion body: EP
  • date: 2018-09-11T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE627.727 title: PE627.727 committee: JURI type: Specific opinion body: EP
  • date: 2018-09-11T00:00:00 docs: title: PE627.728 type: Amendments tabled in committee body: EP
  • date: 2018-09-12T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE620.890&secondRef=03 title: PE620.890 committee: ITRE type: Committee opinion body: EP
  • date: 2018-09-13T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/parlements_nationaux/com/2018/0051/PL_SEJM_AVIS-COM(2018)0051_EN.docx title: PE626.700 type: Reasoned opinion body: PL_SEJM
  • date: 2019-04-16T00:00:00 docs: url: /oeil/spdoc.do?i=31544&j=0&l=en title: SP(2019)354 type: Commission response to text adopted in plenary
  • date: 2018-04-11T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051 type: Contribution body: PL_SENATE
  • date: 2018-04-04T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051 type: Contribution body: PT_PARLIAMENT
  • date: 2018-04-27T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051 type: Contribution body: IE_HOUSES-OF-OIREACHTAS
  • date: 2018-05-02T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2018)0051 title: COM(2018)0051 type: Contribution body: DE_BUNDESRAT
events
  • date: 2018-01-31T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2018/0051/COM_COM(2018)0051_EN.pdf title: COM(2018)0051 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2018&nu_doc=0051 title: EUR-Lex summary: PURPOSE: foster cooperation between EU Member States in health technology assessment. PROPOSED ACT: Regulation of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: Parliament decides in accordance with the ordinary legislative procedure on an equal footing with Council. BACKGROUND: health technology assessment (HTA) is a multidisciplinary process (covering medical, social, economic and ethical issues) and an evidence-based process that independently and objectively assesses a new or existing technology and compares it with other health technologies and / or the current standard of care. Following the adoption of the Cross-Border Healthcare Directive ( Directive 2011/24/EU ), a voluntary European network of HTAs composed of national HTA agencies or bodies was set up (in 2013) to provide strategic and political guidance to the scientific and technical cooperation at Union-level. While Member States have carried out some joint assessments within the framework of the EU co-funded joint actions, the production of output has been inefficient . Use of the results of the joint actions, including their joint clinical assessments, at Member State-level has remained low. The duplication of assessments on the same health technology by HTA authorities and bodies in different Member States within identical or similar timeframes has not been sufficiently addressed. The European Parliament, in its resolution of 2 March 2017 called on the Commission to propose legislation on a European system for health technology assessment and to harmonise transparent health technology assessment criteria in order to assess the added therapeutic value of medicines. IMPACT ASSESSMENT: four policy options were analysed. The preferred option is based on Option 4 ( permanent cooperation on common tools, procedures, early dialogues and joint clinical assessments ), integrating certain elements of Option 2 (project-based cooperation on HTA activities) as well as some adjustments (e.g. transitional arrangements for Member States and progressive implementation of the product scope for joint clinical assessments). CONTENT: the proposed regulation aims to provide the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments of new medicines and certain new medical devices. Its general objectives are to ensure a better functioning of the internal market and to contribute to a high level of protection of human health. The specific objectives are to improve the availability of innovative health technologies for EU patients, to ensure an efficient use of resources and to improve the quality of HTA across th EU, and to improve business predictability. Member States will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas: 1) Joint clinical assessments: these focus on the most innovative health technologies with the most Union-wide and public health impact. These assessments are limited to: medicinal products undergoing the central marketing authorisation procedure, new active substances and existing products for which the marketing authorisation is extended to a new therapeutic indication; and certain classes of medical devices and in vitro diagnostic medical devices which have been selected by the Coordination Group set up under the Regulation. Following the end of a transitional period , participation in the assessments and use of the joint clinical assessment reports at Member State level will be mandatory. Member States will continue to carry out non-clinical assessments (e.g. economic, organisational, ethical) of health technologies and make decisions on pricing and reimbursement. 2) Joint scientific consultations : these allow a developer in the development phase of a health technology to seek the advice of HTA authorities and bodies on the data and evidence likely to be required as part of a potential future joint clinical assessment. 3) Identification of emerging health technologies : This exercise will act as a key input for the annual work programmes, helping to identify at an early stage of their development, the health technologies expected to have a major impact on patients. The Coordination Group will fully consult with all relevant interest groups during this exercise. 4) Voluntary cooperation in other areas : this cooperation could include the assessment of health technologies other than medicinal products or medical devices, non-clinical assessments or collaborative assessments of medical devices not subject to common clinical assessments. Lastly, the proposal lays down common implementing rules in order to ensure harmonisation of the way in which Member States carry out clinical assessments. A key objective of these rules will be to ensure that clinical assessments, whether at EU or at Member State level, are carried out in an independent and transparent manner, free from conflicts of interests. BUDGETARY IMPLICATIONS: the implementation of the proposal has no impact on the current Multiannual Financial Framework 2014-2020 as the current cooperation on HTA is financed by the Public Health Programme. The financial impact on the EU budget post-2020 will be part of the Commission's proposals for the next Multiannual Financial Framework. DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union.
  • date: 2018-02-08T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2018-09-13T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2018-09-24T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0289&language=EN title: A8-0289/2018 summary: The Committee on the Environment, Public Health and Food Safety adopted the report by Soledad CABEZÓN RUIZ (S&D, ES) on the proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU. The committee recommended that the European Parliament's position adopted at first reading under the ordinary legislative procedure should amend the Commission's proposal as follows. Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. It shall not interfere with the exclusive national competence of Member States for national pricing or reimbursement decisions. Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a p recondition for successful cooperation. HTA shall be used to promote innovations that produce the best results for patients and society in general . Health professionals, patients and health institutions need to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks. Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials. Cooperation shall, inter alia : promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools. Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them. However, according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group. Transparency : in order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest , they shall withdraw from the meeting whilst the relevant agenda items are being discussed. In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected. Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
  • date: 2018-10-01T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20181001&type=CRE title: Debate in Parliament
  • date: 2018-10-03T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0369 title: T8-0369/2018 summary: The European Parliament adopted, by 576 votes to 56 with 41 abstentions, amendments to the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU. The matter was referred to the committee for interinstitutional negotiations. The main amendments to the Commission proposal adopted in plenary session concern the following points: Purpose : the proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States. Cooperation in the field of health technology assessment (HTA) : Members considered that the cooperation between HTA authorities shall be based on the principle of good governance , objectivity, independence and transparency. They stressed that trust is a precondition for successful cooperation. The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general . It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks. Members therefore considered that joint clinical assessments should therefore aim to identify the added therapeutic value of new or existing health technologies in comparison with other new or existing health technologies, by undertaking a comparative assessment based on comparative trials. Cooperation shall, inter alia : promote high-quality innovation , steering research towards addressing the unmet diagnostic, therapeutic or procedural needs of healthcare systems as well as steering clinical and social priorities; improve scientific evidence used to inform clinical decision-making, efficiency in use of resources, the sustainability of health systems, patient access to these health technologies, and the competitiveness of the sector through greater predictability and more efficient research; ensure that Member States use the outcome of HTA to augment the scientific evidence that informs decisions to introduce health technologies into their systems; play a role throughout the health technology cycle ; help in decision-making on divestment in cases where a technology becomes obsolete; contribute to improving and harmonising standards of care as well as diagnostic and new-born screening practices across the Union; cover areas such as diagnostics used to supplement treatment, surgical procedures, prevention, screening and health promotion programmes, information and communications technology (ICT) tools. In the absence of a commonly agreed definition of what constitutes a high-quality innovation or therapeutic added value, Members called for such definitions to be adopted at EU level. Avoid duplication : in order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them. However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group. Independence and transparency : a coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation. In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed. The coordination group shall ensure that relevant stakeholders and experts are consulted in its work. In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication . Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected. Membersstressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network , whose independence, transparency and impartiality of decisions would be guaranteed. Financing : in order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding , as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
  • date: 2018-10-03T00:00:00 type: Matter referred back to the committee responsible body: EP
  • date: 2019-02-13T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20190213&type=CRE title: Debate in Parliament
  • date: 2019-02-14T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=31544&l=en title: Results of vote in Parliament
  • date: 2019-02-14T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2019-0120 title: T8-0120/2019 summary: The European Parliament adopted a resolution on the proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU. Parliament’s position adopted at first reading under the ordinary legislative procedure amended the Commission proposal as follows: The proposed Regulation shall define a support framework and procedures for cooperation on clinical assessment of health technologies at Union level and common methodologies for the clinical assessment of health technologies. Pricing and reimbursement of medicines shall fall within the exclusive national competence of the Member States. The amended text stipulated that HTA shall be used to promote innovations that produce the best results for patients and society in general. It should enable health professionals, patients and health institutions to know whether or not a new health technology represents an improvement on existing health technologies, in terms of benefits and risks Independence and transparency Cooperation should be based on the principle of good governance, which encompasses transparency, objectivity, independent experience and fair procedures. Members insisted that trust is a precondition for successful cooperation. A coordination group composed of representatives from Member States' health technology assessment authorities and bodies should be established with responsibility and proven expertise for overseeing the carrying out of joint clinical assessments and other joint work within the scope of this Regulation. In order to ensure high quality of work, members of the Coordination Group shall be drawn from national or regional health technology assessment agencies or bodies responsible for that field. Members serving in the Coordination Group, and experts and assessors in general, shall not have financial interests in any type of health technology developer industry or insurance company that may affect their impartiality. They shall undertake to act independently and in the public interest and shall make an annual declaration of interests. In the event of a conflict of interest, they shall withdraw from the meeting whilst the relevant agenda items are being discussed. The coordination group shall ensure that relevant stakeholders and experts are consulted in its work. In addition, in order to ensure transparency and public awareness of the process and to promote confidence in the system, all clinical data being evaluated shall have the highest level of transparency and public communication. Where data is confidential for commercial reasons, its confidentiality shall be clearly defined and justified and the confidential data shall be well delimitated and protected. Parliament stressed the need to ensure a dialogue between the coordination group and patient organisations, consumer organisations, non-governmental health organisations, experts and health professionals, in particular through a stakeholder network, whose independence, transparency and impartiality of decisions would be guaranteed. Joint clinical assessment report The report shall be accompanied by a summary report, which shall contain at least the clinical data compared, the end-points, the comparators, the methodology, the clinical evidence used, and conclusions as regards efficacy, safety, and relative efficacy, the limits of the assessment, diverging views, a summary of the consultations carried out, and the observations made. The report should be accompanied by a summary report including at least the following elements: (i) comparative clinical data, (ii) efficacy criteria, (iii) efficacy criteria, (iii) comparators, (iv) method, (iii) clinical data used, (iv) conclusions on effectiveness and safety, relative efficacy and evaluation limitations, (v) divergent positions, (vi) summary of consultations carried out and comments received. The conclusions of the joint clinical assessment report shall include: - an analysis of the relative effectiveness and safety of the health technology being assessed in terms of the clinical end-points relevant to the clinical entity and patient group chosen for the assessment, including mortality, morbidity and quality of life; - the degree of certainty of relative effects based on the best available clinical data and compared to the best standard therapies. Avoid duplication In order for harmonised procedures to achieve their objective of the internal market and improving innovation and the quality of clinical evidence, Member States shall take account of the results of joint clinical assessments and not repeat them. However, the amended text stated that according to national needs, Member States shall have the right to complement the joint clinical assessments with additional clinical evidence and analyses to account for differences in comparators or the national specific treatment setting. Such complementary clinical assessments shall be duly justified and proportionate and shall be notified to the Commission and the Coordination Group. Financing In order to ensure the availability of sufficient resources for joint work and stable administrative support provided for in the Regulation, the Union shall ensure stable and permanent public funding, as provided for in the multiannual financial framework, for joint work and voluntary cooperation, as well as for the support framework for these activities. Member States shall also have the possibility to second national experts to the Commission in order to support the secretariat of the coordination group.
other
  • body: EC dg: url: http://ec.europa.eu/info/departments/health-and-food-safety_en title: Health and Food Safety commissioner: ANDRIUKAITIS Vytenis Povilas
otherinst
  • name: European Economic and Social Committee
  • name: European Committee of the Regions
procedure/Mandatory consultation of other institutions
European Economic and Social Committee European Committee of the Regions
procedure/Modified legal basis
Rules of Procedure EP 159
procedure/dossier_of_the_committee
Old
ENVI/8/12220
New
  • ENVI/8/12220
procedure/instrument
Old
Regulation
New
  • Regulation
  • Amending Directive 2011/24/EU 2008/0142(COD)
procedure/legal_basis/0
Rules of Procedure EP 59-p4
procedure/other_consulted_institutions
European Economic and Social Committee European Committee of the Regions
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Council 1st reading position / budgetary conciliation convocation
procedure/subject
Old
  • 4.20.05 Health legislation and policy
New
4.20.05
Health legislation and policy
procedure/summary
  • Amending Directive 2011/24/EU
activities/0/commission/0
DG
Commissioner
ANDRIUKAITIS Vytenis Povilas
activities/0/docs/0/text
  • PURPOSE: foster cooperation between EU Member States in health technology assessment.

    PROPOSED ACT: Regulation of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: Parliament decides in accordance with the ordinary legislative procedure on an equal footing with Council.

    BACKGROUND: health technology assessment (HTA) is a multidisciplinary process (covering medical, social, economic and ethical issues) and an evidence-based process that independently and objectively assesses a new or existing technology and compares it with other health technologies and / or the current standard of care.

    Following the adoption of the Cross-Border Healthcare Directive (Directive 2011/24/EU), a voluntary European network of HTAs composed of national HTA agencies or bodies was set up (in 2013) to provide strategic and political guidance to the scientific and technical cooperation at Union-level.

    While Member States have carried out some joint assessments within the framework of the EU co-funded joint actions, the production of output has been inefficient. Use of the results of the joint actions, including their joint clinical assessments, at Member State-level has remained low. The duplication of assessments on the same health technology by HTA authorities and bodies in different Member States within identical or similar timeframes has not been sufficiently addressed.

    The European Parliament, in its resolution of 2 March 2017 called on the Commission to propose legislation on a European system for health technology assessment and to harmonise transparent health technology assessment criteria in order to assess the added therapeutic value of medicines.

    IMPACT ASSESSMENT: four policy options were analysed. The preferred option is based on Option 4 (permanent cooperation on common tools, procedures, early dialogues and joint clinical assessments), integrating certain elements of Option 2 (project-based cooperation on HTA activities) as well as some adjustments (e.g. transitional arrangements for Member States and progressive implementation of the product scope for joint clinical assessments).

    CONTENT: the proposed regulation aims to provide the basis for permanent and sustainable cooperation at the EU level for joint clinical assessments of new medicines and certain new medical devices. Its general objectives are to ensure a better functioning of the internal market and to contribute to a high level of protection of human health. The specific objectives are to improve the availability of innovative health technologies for EU patients, to ensure an efficient use of resources and to improve the quality of HTA across th EU, and to improve business predictability.

    Member States will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas:

    1) Joint clinical assessments: these focus on the most innovative health technologies with the most Union-wide and public health impact. These assessments are limited to:

    • medicinal products undergoing the central marketing authorisation procedure, new active substances and existing products for which the marketing authorisation is extended to a new therapeutic indication; and
    • certain classes of medical devices and in vitro diagnostic medical devices which have been selected by the Coordination Group set up under the Regulation.

    Following the end of a transitional period, participation in the assessments and use of the joint clinical assessment reports at Member State level will be mandatory. Member States will continue to carry out non-clinical assessments (e.g. economic, organisational, ethical) of health technologies and make decisions on pricing and reimbursement.

    2) Joint scientific consultations: these allow a developer in the development phase of a health technology to seek the advice of HTA authorities and bodies on the data and evidence likely to be required as part of a potential future joint clinical assessment.

    3) Identification of emerging health technologies: This exercise will act as a key input for the annual work programmes, helping to identify at an early stage of their development, the health technologies expected to have a major impact on patients. The Coordination Group will fully consult with all relevant interest groups during this exercise.

    4) Voluntary cooperation in other areas: this cooperation could include the assessment of health technologies other than medicinal products or medical devices, non-clinical assessments or collaborative assessments of medical devices not subject to common clinical assessments.

    Lastly, the proposal lays down common implementing rules in order to ensure harmonisation of the way in which Member States carry out clinical assessments. A key objective of these rules will be to ensure that clinical assessments, whether at EU or at Member State level, are carried out in an independent and transparent manner, free from conflicts of interests.

    BUDGETARY IMPLICATIONS: the implementation of the proposal has no impact on the current Multiannual Financial Framework 2014-2020 as the current cooperation on HTA is financed by the Public Health Programme. The financial impact on the EU budget post-2020 will be part of the Commission's proposals for the next Multiannual Financial Framework.

    DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in accordance with Article 290 of the Treaty on the Functioning of the European Union.

activities/1/committees/2/date
2018-02-26T00:00:00
activities/1/committees/2/rapporteur
  • group: S&D name: CABEZÓN RUIZ Soledad
activities/1/committees/2/shadows
  • group: EPP name: GROSSETÊTE Françoise
  • group: ECR name: PIECHA Bolesław G.
  • group: ALDE name: MEISSNER Gesine
  • group: GUE/NGL name: KONEČNÁ Kateřina
  • group: Verts/ALE name: RIVASI Michèle
  • group: EFD name: PEDICINI Piernicola
  • group: ENF name: MÉLIN Joëlle
activities/1/committees/4/date
2018-03-21T00:00:00
activities/1/committees/4/rapporteur
  • group: EPP name: BUŞOI Cristian-Silviu
activities/1/committees/5/date
2018-03-15T00:00:00
activities/1/committees/5/rapporteur
  • group: ALDE name: WIERINCK Lieve
activities/1/committees/7
body
EP
responsible
None
committee
JURI
date
2018-07-26T00:00:00
committee_full
Legal Affairs
rapporteur
group: EPP name: VOSS Axel
committees/2/date
2018-02-26T00:00:00
committees/2/rapporteur
  • group: S&D name: CABEZÓN RUIZ Soledad
committees/2/shadows
  • group: EPP name: GROSSETÊTE Françoise
  • group: ECR name: PIECHA Bolesław G.
  • group: ALDE name: MEISSNER Gesine
  • group: GUE/NGL name: KONEČNÁ Kateřina
  • group: Verts/ALE name: RIVASI Michèle
  • group: EFD name: PEDICINI Piernicola
  • group: ENF name: MÉLIN Joëlle
committees/4/date
2018-03-21T00:00:00
committees/4/rapporteur
  • group: EPP name: BUŞOI Cristian-Silviu
committees/5/date
2018-03-15T00:00:00
committees/5/rapporteur
  • group: ALDE name: WIERINCK Lieve
committees/7
body
EP
responsible
None
committee
JURI
date
2018-07-26T00:00:00
committee_full
Legal Affairs
rapporteur
group: EPP name: VOSS Axel
links/Research document
url
http://www.europarl.europa.eu/thinktank/en/document.html?reference=EPRS_BRI(2018)614772
title
Briefing
other/0
body
EC
dg
commissioner
ANDRIUKAITIS Vytenis Povilas
activities
  • date: 2018-01-31T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2018/0051/COM_COM(2018)0051_EN.pdf celexid: CELEX:52018PC0051:EN type: Legislative proposal published title: COM(2018)0051 type: Legislative proposal published body: EC commission:
  • date: 2018-02-08T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: False committee_full: Economic and Monetary Affairs committee: ECON body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Women’s Rights and Gender Equality committee: FEMM body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee_full: Legal Affairs committee: JURI
committees
  • body: EP responsible: False committee_full: Economic and Monetary Affairs committee: ECON
  • body: EP responsible: False committee_full: Employment and Social Affairs committee: EMPL
  • body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: False committee_full: Women’s Rights and Gender Equality committee: FEMM
  • body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO
  • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • body: EP responsible: False committee_full: Legal Affairs committee: JURI
links
other
    procedure
    dossier_of_the_committee
    ENVI/8/12220
    Mandatory consultation of other institutions
    European Economic and Social Committee European Committee of the Regions
    reference
    2018/0018(COD)
    instrument
    Regulation
    legal_basis
    Treaty on the Functioning of the EU TFEU 114
    stage_reached
    Awaiting committee decision
    summary
    Amending Directive 2011/24/EU
    subtype
    Legislation
    title
    Health technology assessment
    type
    COD - Ordinary legislative procedure (ex-codecision procedure)
    subject
    4.20.05 Health legislation and policy